401 related articles for article (PubMed ID: 12091599)
21. Non-erythropoietin-based anaemia management in chronic kidney disease.
Hörl WH
Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.
Cody JD; Hodson EM
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD003266. PubMed ID: 26790135
[TBL] [Abstract][Full Text] [Related]
23. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
24. [Anemia in peritoneal dialysis patients].
Lausević M; Nesić V; Jovanović N; Stojimirović B
Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
[TBL] [Abstract][Full Text] [Related]
25. [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Pol Arch Med Wewn; 1995 Aug; 94(2):144-52. PubMed ID: 8596749
[TBL] [Abstract][Full Text] [Related]
26. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
[TBL] [Abstract][Full Text] [Related]
27. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
Macdougall IC
Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
[TBL] [Abstract][Full Text] [Related]
28. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients.
Cheng IK; Lu HB; Wei DC; Cheng SW; Chan CY; Lee FC
Am J Nephrol; 1993; 13(2):142-8. PubMed ID: 8342581
[TBL] [Abstract][Full Text] [Related]
29. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
30. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.
Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
Blood; 1993 Oct; 82(7):2010-6. PubMed ID: 8400253
[TBL] [Abstract][Full Text] [Related]
31. Anemia of renal failure. Use of erythropoietin.
Humphries JE
Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
[TBL] [Abstract][Full Text] [Related]
32. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
[TBL] [Abstract][Full Text] [Related]
34. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.
Jungers P; Choukroun G; Oualim Z; Robino C; Nguyen AT; Man NK
Nephrol Dial Transplant; 2001 Feb; 16(2):307-12. PubMed ID: 11158405
[TBL] [Abstract][Full Text] [Related]
35. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study.
Branger B; Vécina F; Zabadani B; Balducchi JP; Fourcade J
Nephrol Dial Transplant; 1995; 10 Suppl 6():36-9. PubMed ID: 8524492
[TBL] [Abstract][Full Text] [Related]
37. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
[TBL] [Abstract][Full Text] [Related]
39. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability.
Linde T; Sandhagen B; Wikström B; Danielson BG
Nephrol Dial Transplant; 1997 Nov; 12(11):2375-9. PubMed ID: 9394325
[TBL] [Abstract][Full Text] [Related]
40. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
Sitter T; Bergner A; Schiffl H
Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
